

(NON-CONVENTION—Company)

34351/89

AC

FORM 7—REGULATION 12 (1)
COMMONWEALTH OF AUSTRALIA

PATENTS ACT, 1952-1973

DECLARATION IN SUPPORT OF AN APPLICATION FOR A PATENT.

(a) Here Insert (in full)
Name of Company.

In support of the Application made by (a)

SMITHKLINE BEECHAM CORPORATION

(hereinafter referred to as "Applicant") for a patent for an invention entitled:

(b) Here Insert Title of
invention.

"TOPICALLY APPLIED GOLD ORGANIC COMPLEX"

(c) Here Insert Full
Name and Address of
Company Official
authorised to make
Declaration.

I, (c) Stuart Ross Suter
Of 336 Woods Road, Glenside, Pennsylvania 19038,
United States of America

do solemnly and sincerely declare as follows:

1. I am authorised by Applicant to make this declaration on its behalf.

(d) Here Insert (in full)
Name and Address of
Actual Inventor(s).

2. (d) Ralph Anthony PAPANDREA

10 Seaview Parade,
Collaroy, New South Wales 2097,
Australia

is/are

the actual inventor(s) of the invention and the facts upon which Applicant is
entitled to make the Application are as follows:

~~Applicant is the Assignee of the said Inventor(s)~~

Applicant is the Assignee of Top Gold Pty. Ltd. which
is the Assignee of the said Inventor.

Declared at Philadelphia, Pennsylvania, U.S.A.
this 18th day of September, 1990.

SMITHKLINE BEECHAM CORPORATION

(e) Personal Signature
of Declarant (c) (no
seal, witness or
legalisation).

(e) BY:

Stuart Ross Suter
Vice President & Patent Counsel
Corporate Patents - U.S.

To THE COMMISSIONER OF PATENTS.

SHELSTON WATERS

PATENT ATTORNEYS
55 CLARENCE STREET, SYDNEY
AUSTRALIA

Cables: 'Valid' Sydney Telex: 24422

SW

(12) PATENT ABRIDGMENT (11) Document No. AU-B-34351/89
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 616755

(54) Title
TOPICALLY APPLIED GOLD ORGANIC COMPLEX

International Patent Classification(s)
(51)⁴ A61K 031/28 A61K 031/70

(21) Application No. : 34351/89

(22) Application Date : 22.03.89

(87) PCT Publication Number : WO89/09054

(30) Priority Data

(31) Number	(32) Date	(33) Country
PI7387	23.03.88	AU AUSTRALIA
PI7480	28.03.88	AU AUSTRALIA
PI9878	15.08.88	AU AUSTRALIA
PJ2313	18.01.89	AU AUSTRALIA

(43) Publication Date : 16.10.89

(44) Publication Date of Accepted Application : 07.11.91

(71) Applicant(s)
SMITHKLINE BEECHAM CORPORATION


(72) Inventor(s)
RALPH ANTHONY PAPANDREA

(74) Attorney or Agent
SHELSTON WATERS, 55 Clarence Street, SYDNEY NSW 2000

(57) Claim

1. A pharmaceutical composition for topical application comprising a gold compound (as hereinbefore defined) and a pharmaceutically acceptable topical carrier having viscosity greater than that of water.

4. A composition according to claim 3 wherein the gold compound has the following structure:




wherein X is H, acetyl or formyl and A is -S-Au-PR₃ or -Y-(CH₂)_n S-Au PR₃; wherein R is H, alkyl, aryl or heterocyclic and may be substituted or unsubstituted; Y is O or S; and n is from 1 to 12

5. A composition according to claim 4 wherein the gold compound has the following structure:

(11) AU-B-34351/89
(10) 616755

-2-



616755

OPI DATE 16/10/89

APPLN. ID

34351 / 89

AORP DATE 09/11/89

PCT NUMBER PCT/AU89/00118

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 31/28, 31/70		A1	(11) International Publication Number: WO 89/ 09054
			(43) International Publication Date: 5 October 1989 (05.10.89)
(21) International Application Number: PCT/AU89/00118		(72) Inventor; and	
(22) International Filing Date: 22 March 1989 (22.03.89)		(75) Inventor/Applicant (for US only) : PAPANDREA, Ralph, Anthony [AU/AU]; 10 Seaview Parade, Collaroy, NSW 2097 (AU).	
(31) Priority Application Numbers:		PI 7387 PI 7480 PI 9878 PJ 2313	(74) Agent: SHELSTON WATERS; 55 Clarence Street, Sydney, NSW 2000 (AU).
(32) Priority Dates:		23 March 1988 (23.03.88) 28 March 1988 (28.03.88) 15 August 1988 (15.08.88) 18 January 1989 (18.01.89)	(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, ML (OAPI patent), NL (European patent), SN, TG (OAPI patent)
(33) Priority Country: AU			
(71) SECTION 34(4)(a) DIRECTION SEE FOLIO NAME DIRECTED SMITHKLINE BEECHAM of the Australian Patent Office, Collaroy, NSW 2097 (AU).			
		Published With international search report.	
(54) Title: TOPICALLY APPLIED GOLD ORGANIC COMPLEX			
(57) Abstract			
It has been surprisingly found that gold compounds may be applied in topical preparations as an effective treatment of local or systemic inflammatory conditions and/or as antibacterial agents. The present invention therefore relates to new pharmaceutical compositions containing gold for topical application, and the use of the composition in treating inflammation and/or bacterial infection.			

- 1 -

TITLE: TOPICALLY APPLIED GOLD ORGANIC COMPLEX

The present invention pertains to topically applied pharmaceutical compositions of gold compounds and their use in the treatment of psoriasis and as antibacterial agents.

BACKGROUND

Elemental gold was believed in ancient times to have various curative properties. However, in the 1960s the effectiveness of simple inorganic gold salts administered intravenously was demonstrated in the treatment of rheumatoid arthritis. Subsequently, aurothiomalate and aurothioglucose administered in parenteral form were found to be more effective. These are water soluble complexes containing approximately 50% of gold by weight and having thiolate ligands. Gold thiopolypeptide has also been injected. Aucanofin, a lipid soluble complex containing approximately 29% of gold by weight and having

- 2 -

a phosphine and a sulphur ligand, has been administered orally.

Gold compounds (which term is herein used generally to embrace complexes in which gold is chelated or bound to one or more ligands, organo-gold compounds, inorganic gold compounds and salts thereof) have thus hitherto been administered for therapeutic purposes only by the parenteral or by the oral route and for the treatment of asthma, tuberculosis, pemphigus vulgaris, various forms of arthritis, cancer and infection.

Despite established clinical efficacy, the mechanism of action of gold compounds in the treatment of the above conditions is unknown, although it is appreciated that different chemical forms of gold have varying efficacy with respect to treating the above disorders.

Gold is a transition state metal that is capable of forming complexes in oxidation states I and III, namely:

-Au- Gold I

$\begin{array}{c} \diagup \\ \text{Au} \\ \diagdown \end{array}$ Gold III

The chemistry of gold compounds is complicated by the tendency of many compounds to form complex polymers.

Another complication is that gold compounds may undergo extensive modification in the body to produce the active species.

- 3 -

Finally there appears to be no correlation between blood levels of the various gold compounds and biological activity.

The biological activity of gold compounds is not determined solely by the presence of gold itself but also depends on:-

- a. the oxidation state (I or III)
- b. the degree of polymerization
- c. the types of ligands
- d. the stereochemistry of the molecule

Suggested mechanisms for the action of gold drugs include:-

- a. modulation of humoral and cell-mediated immunity,
- b. inhibition of the formation of immune complexes and/or the transmitter substances released as a consequence of the immune complex formation,
- c. inhibition of the formation and/or release of lysosomal enzymes,
- d. inhibition of the formation and/or action of prostaglandins,
- e. inhibition of the proliferation of synovial and other cell types including cancer cells,
- f. modulation of copper and zinc metabolism,
- g. enzyme inhibition.

Orally administered auranofin exhibits protracted blood levels of gold in comparison with parentally administered gold compounds and is minimally retained in

- 4 -

tissue. Both the parenteral and oral routes of administration have been known to produce severe renal, haematological and other adverse effects including skin and mucuous membrane lesions in some cases. Severe gastrointestinal upsets frequently occur following the use of oral gold.

It is known that synovial membrane, particularly when inflamed, may show selective uptake of injected or orally administered gold initially, after which it is distributed to the other tissues.

An example of selective activity is shown by auranofin which possesses greater affinity for penetration of lymphocyte membranes than do many other gold compounds, particularly those of the hydrophilic type.

In 1984 Brown et al applied a water soluble and a lipid soluble gold complex as a solution in ethanol to the skin of rats in order to measure the levels of gold absorbed into the blood stream through topical application. It was concluded that the lipid soluble complex was more rapidly absorbed into the blood than the water soluble complex and that blood absorption levels were comparable with oral administration. However, no corresponding tests have been reported on human skin, and studies have not shown correlation between blood levels of gold and clinical effectiveness in treatment of any of the foregoing diseases either in rats or in humans.

- 5 -

It has now been surprisingly discovered that gold compounds administered topically are in some circumstances significantly more effective than gold compounds administered via parenteral or oral routes while avoiding or ameliorating the disadvantages previously discussed.

It has also been surprisingly found that gold compounds administered topically are efficacious in the treatment of local and systemic inflammatory conditions such as psoriasis and rheumatoid arthritis and/or as antibacterial agents.

It has also been found that gold compounds topically applied act synergistically with corticosteroids in the therapeutic treatment of local inflammatory conditions, particularly psoriasis.

SUMMARY OF THE INVENTION

In one aspect the present invention therefore resides in the use of topical applications of a gold compound (as hereinbefore defined) to treat local and systemic inflammatory conditions, particularly psoriasis and rheumatoid arthritis.

According to a second aspect the present invention consists in a composition for topical application comprising a gold compound in combination with a pharmaceutically acceptable carrier having viscosity greater than that of water.

- 6 -

According to a third aspect the invention consists in a method for treatment of the inflamed region of a patient suffering from inflammation comprising the step of applying a gold compound to the skin at or in the vicinity of the inflammation.

Preferably, the gold compounds used in the present invention are lipid soluble.

In a preferred embodiment, ~~the present invention~~ resides in the synergistic mixture of gold compounds and corticosteroids.

The combination of gold compounds and corticosteroids has been surprisingly found to increase therapeutic effectiveness and to also decrease adverse effects.

It has surprisingly also been found that gold compounds are effective against a range of pathogenic bacteria including gram negative and gram positive bacteria, and particularly effective against gram positive bacteria.

BEST METHOD OF PERFORMANCE


The invention will now be more particularly described with reference to specific embodiments by way of example only.

Most gold compounds in use are hydrophilic, a major exception being gold phosphine compounds of the type:




where R is methyl, ethyl, iso-propyl or n-butyl,

- 7 -




where R is alkyl, alkoxy or phenyl, and
R' is H, alkyl, aryl or heterocyclic and may be
substituted or unsubstituted.

Preferred R' moieties include substituted
carbohydrates and




wherein R'' is alkyl or H; and



where R, all of which may be the same or different,
may be alky, aryl or heterocyclic and may be substituted
or unsubstituted.

A clinically used example is auranofin:



- 8 -

Preferred compounds for use in the present invention include gold (I) phosphines and related compounds, gold (I) phosphine (or phosphite) thiolates, bis-coordinated gold (I) salts and gold (I) chelates.

The most preferred corticosteroid used in conjunction with gold compounds in a preferred embodiment of this invention is ~~betamethasone dipropionate~~, although other corticosteroids may be equally as effective.

PHARMACEUTICAL FORMULATIONS

Suitable pharmaceutical formulations for the application of gold compounds to the skin include liquids, powders, gels, ointments, creams, sprays, including metered aerosol sprays, and patches. The choice of formulation depends on the intended therapeutic use.

Choice of formulation for topical use depends on the type and location of the lesion. The formulation may include stabilizers and/or penetration agents or the like. For general topical use a hydrophobic emulsifiable ointment base produces satisfactory results, however, any other formulation for topical application may be equally applicable, for example monohydric, dihydric and trihydric alkanols. The alcohols may be short chain (C_1 to C_{10}) alcohols or long chain (C_{12} to C_{20}) alcohols.

Especially preferred are polyhydric alcohols such as diethylene glycol or glycerol. A simple hydrocarbon base is also effective.

Compounds according to the invention are believed to

be efficacious in the alleviation of symptoms of inflammatory disease when applied topically in both humans and animals. It is believed that the compositions are effective at comparatively low concentrations and that therefore the side effects are minimized in comparison with other means of gold administration. Preferably the concentration of the gold compound in the pharmaceutical formulation may be between about 0.05 and 0.25% by weight of the total composition.

It is further preferred that formulations made in accordance with the present invention may sometimes contain a keratolytic substance, further preferably being salicylic acid. Alternatively, ointments containing heparinoid and hyaluronidase may facilitate absorption of auranofin.

Preferably, the base ointment is a wool alcohol ointment or a simple hydrocarbon base.

EXAMPLE 1

Formulation of Auranofin Ointment

Ingredients

Ridaura (auranofin) tabs (3 mg).....	60 tabs
Alcohol (90%).....	20 mL
Propylene glycol.....	5 mL
Ointment of Wool Alcohols to.....	100 g

Preparation

Ridaura tablets were ground in a glass mortar and alcohol added. This was allowed to soak for 15 min,



- 9a -

then ground for 15 min, by which time most of the alcohol had evaporated. Propylene glycol was added and the mixture ground for a further 10 min. The contents

100
100
100
100



- 10 -

of the mortar were weighed and Ointment of Wool Alcohols added to weight.

It is anticipated that commercially prepared auranofin ointment would be made from pure auranofin powder not tablets.

In another preferred method of preparing the ointment, the auranofin powder is triturated with mineral, vegetable or fish oil. The ointment base is then added. The latter can be a pure hydrocarbon base or can contain emulsifying agents such as wool alcohols.

It is well recognized that the formulations in which topical drugs are presented can influence clinical efficacy. The addition of adjuncts such as propylene glycol and urea, can facilitate the extent to which the active drug penetrates the skin.

In inflammatory skin diseases, the barrier to absorption is often disrupted allowing significant systemic absorption of drugs that are normally not absorbed percutaneously. In other skin conditions, intense scaling or lichenification can impede the local penetration of the drug. A similar situation occurs when the condition occurs on the palms and soles. In such cases, the keratolytic agents, either added to the formulation or used prior to treatment with the active drug, may be needed if the drug is to reach its site of action in the skin.

- 11 -

Formulations may be varied depending on the condition and location of psoriatic lesions. A greasy formulation such as those mentioned above are not suitable for application to the scalp. Consequently, the formulation may be varied by those skilled in the art to achieve the desired consistency.

EXAMPLE 2

Alternative Formulation

Propylene glycol.....	10 ml
Auranofin.....	1.8 mg/g
Lasonil® ointment.....	14 g
Diprosone® ointment.....	15 g
Wool Alcohol Ointment to.....	90 g

This formulation gives a final concentration of betamethasone dipropionate of approximately 0.008%.

Although only compositions containing Auranofin have been exemplified herein, it is proposed that equivalent compositions containing any one, or a combination of the following gold compounds may be equally effective.

• LASONIL is a trade mark of Bayer and contains 5,000 HDBY heparinoid and 15,000 units of hyaluronidase per 100g ointment.

DIPROSONE is a trade mark of Schering and contains 0.05% Betamethasone as the dipropionate.

EXAMPLE 3

The preferred gold (I) phosphines and related compounds have the general formula:



wherein R is alkyl, aryl or heterocyclic, and may be further substituted; and X is halogen.

Preferred examples include Et_3PAuCl and Ph_3PAuCl , wherein Ph is phenyl and Et is ethyl.

Compounds of formula I may be prepared by reacting an ethanolic solution of $HAuX_4$ (1 mol) and R_3P (2 mol), or from reacting AuX and PR_3 . Compounds produced by these methods have high lipid solubility.

Related compounds useful in the performance of the present invention include trialkyl phosphites of the formula:



and thiocynate complexes of the formulae



and



wherein R and X are as described above. Preferably R is ethyl or phenyl.


EXAMPLE 4

The preferred gold (I) phosphine (or phosphite) thiolates of the present invention have the general formula:




wherein R and R¹ may be H, alkyl, aryl or heterocyclic and may be substituted or unsubstituted.

Preferred examples include those in which R is ethyl or phenyl, and R¹ is a substituted carbohydrate moiety resulting in compounds such as



or



wherein X is H, acetyl or formyl; Y is O or S; and n is 1-12.

Another preferred example of this type of compound is (C₂H₅)₃PAuS-CH-CH₂-COOC₂H₅ where the CH group is also substituted with a COOC₂H₅ group.

(IIc)

The following illustrates a preferred synthetic pathway employed in producing the above compounds:



- 14 -

Other examples of appropriate compounds include phosphine or phosphite Au(I) complexes including derivatives of thioalcohols (eg $R_3PAuSCH(R^1)CH(R^2)OR^3$), thioacids (eg $R_3PAuSCH(R^1)CH(R^2)COOR^3$), thiophenols (eg $R_3PAuSC_6H_4R^2$) where $R^1, R^2, R^3 = H$, alkyl, aryl or heterocyclic and may be substituted or unsubstituted. In the case of thiophenols, R^2 may be any group eg NH_2 .



Other examples of suitable compounds of this case include R_3PAuX where $X =$ moieties such as 2-thiazoliny1, thio-2-benzimidazolyl and 2-benzoxazolylthio- Large ring chelate compounds such as the following are also suitable compounds



where $R = H$, alkyl, aryl or heterocyclic and may be substituted or unsubstituted. Also suitable is $(R_3PAu)_2S$.

EXAMPLE 5

The preferred bis-coordinated gold (I) salts have general formulae of the following type:



wherein R is alkyl, aryl or heterocyclic and can be either substituted or unsubstituted; and X is halide,

- 15 -

ClO_4 , BF_4 or any monovalent or divalent anion known in the art.

EXAMPLE 6

The preferred gold (I) chelates have the following formula:



wherein R is any suitable bridging moiety and may be substituted or unsubstituted alkyl, aryl or heterocyclic; X is O, N or SO_2NR_2 and R^1 is H, alkyl, aryl or heterocyclic and may be substituted or unsubstituted.

A preferred example is where R is C_6H_4 , X is O and R^1 is C_2H_5 .

EXAMPLE 7

Preliminary studies in 19 human subjects with psoriasis showed remarkable therapeutic efficacy and limited signs or symptoms of adverse effects.

One subject was an elderly male with a long history of severe psoriasis that did not respond well to conventional therapy. Under the direction of a dermatologist, auranofin ointment (1.8 mg/g) was applied to a large area of the patient's back and a small area of the left leg. Placebo ointment was applied to the chest and a small area of the right leg. The patient did not know which ointment was active and which was placebo.

- 16 -

During the course of one week 80 g of ointment was applied equivalent to 144 mg of auranofin.

At the end of the first week, a marked improvement in the patient's condition was observed with respect to the areas treated with the active drug. Both patient and attending dermatologist agreed that the improvement was superior to that achieved in the same time interval by any other remedy previously used by this patient. The areas of skin treated with placebo ointment did not improve and may have worsened during the first week.

The patient was then treated with a weaker strength ointment but the condition continued to improve.

Another subject to receive auranofin ointment suffered from mild psoriasis. This person applied the ointment to a small patch of psoriasis and found significant resolution after three days. Beneficial results were also obtained with the other 17 subjects.

Choice of formulation for topical use depends on the type and location of the lesion. The formulation may include stabilizers and/or penetration agents or the like. For general topical use a hydrophobic emulsifiable ointment base produces satisfactory results, however, any other formulation for topical application may be equally applicable, for example monohydric, dihydric and trihydric alkanols. The alcohols may be short chain (C_1 to C_{10}) alcohols or long chain (C_{12} to C_{20}) alcohols.

- 17 -

Especially preferred are polyhydric alcohols such as diethylene glycol or glycerol.

It appears that topical auranofin products should be available in at least two strengths, 0.2% and 0.1%. For maximum effectiveness, additional therapeutic agents may be necessary. For example, where there is intense scaling, prior application of a keratolytic agent may be necessary.

In view of the evidence for synergistic effect⁹ between auranofin and corticosteroids, concomitant or sequential use of these agents would seem an appropriate strategy. It would also seem that auranofin applied to skin persists for some time following discontinuation of the drug and thus the synergism between the steroid and auranofin would appear to persist after the auranofin has been discontinued.

Auranofin has features that could make it a very acceptable topical drug if properly formulated. It appears to be very effective as well as being cosmetically acceptable and much easier and more pleasant to use than many of the conventional therapies. It is not possible to give any indication of the likely incidence of adverse effects based on the limited number of cases studied. However its potential risk would seem to be much less than that of other powerful drugs used in the treatment of psoriasis such as methotrexate and etretinate. It would also seem to be more


- 18 -

therapeutically effective than these drugs. Although the corticosteroids can be quite effective in psoriasis, the need, in some patients, to use them on a continuous basis carries the risk of skin atrophy plus undesirable systemic effects to which prolonged use on damaged skin can lead.

As will be apparent to those skilled in the art from the teaching hereof, gold compounds other than those exemplified herein may be selected on the basis of their lipid solubility and such compounds, when included in the formulation for topical application, are comprehended within the scope of this invention.


CLAIMS

1. A pharmaceutical composition for topical application comprising a gold compound (as hereinbefore defined) and a pharmaceutically acceptable topical carrier having viscosity greater than that of water.
2. A composition according to claim 1 wherein the gold compound is lipid soluble.
3. A composition according to claim 2 wherein the gold compound is in oxidation state I.
4. A composition according to claim 3 wherein the gold compound has the following structure:



wherein X is H, acetyl or formyl and A is $-S-Au-PR_3$ or $-Y-(CH_2)_n S-Au PR_3$; wherein R is H, alkyl, aryl or heterocyclic and may be substituted or unsubstituted; Y is O or S; and n is from 1 to 12


5. A composition according to claim 4 wherein the gold compound has the following structure:



6. [AMENDED] A composition according to any one of claims 1 to 5 further comprising a corticosteroid.




7. A composition according to claim 6 wherein the corticosteroid is betamethasone dipropionate.
8. A pharmaceutical composition for topical application comprising a gold compound having the following structure:



wherein X is H, acetyl or formyl and A is $-S-Au-PR_3$ or $-Y-(CH_2)_n S-Au PR_3$; wherein R is H, alkyl, aryl or heterocyclic and may be substituted or unsubstituted; Y is O or S; and n is from 1 to 12; together with betamethasone dipropionate and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition according to claim 8 wherein the gold compound has the following structure:



10. A pharmaceutical composition according to claim 9 wherein the concentration of the gold compound is between 0.05 and 0.25% by weight of the total composition.
11. A composition according to any one of claims 8-10 wherein the carrier is an ointment.
12. The use of topical applications of a gold compound (as hereinbefore defined) in the treatment of a local or systemic inflammatory condition.



13. The use of topical applications according to claim 12 wherein the condition is psoriasis.
14. The use of topical applications of a gold compound (as hereinbefore defined) as antibacterial agents.
15. The use of topical applications according to claim 14 wherein the bacteria are gram positive.
16. The use of a composition according to claim 1 in the treatment of psoriasis.
17. The use of a composition according to claim 5 in the treatment of psoriasis.
18. The use of a composition according to claim 9 in the treatment of psoriasis.
19. A method of topically treating local or systemic inflammatory conditions comprising applying a pharmaceutical composition containing a gold compound (as hereinbefore defined) to or in the vicinity of the inflamed region of a patient suffering from said condition.
20. A method according to claim 19 wherein the inflamed region is a region on a patient suffering from psoriasis.
21. A method of treating bacterial infection comprising applying a pharmaceutical composition containing a gold compound (as hereinbefore defined) to the site of said infection.
22. A method of treating psoriasis comprising the step of applying a pharmaceutical composition according to claim 5 to or in the vicinity of the inflamed region of



a patient suffering from psoriasis.

23. A method of treating psoriasis comprising the step of applying a pharmaceutical composition according to claim 9 to or in the vicinity of the inflamed region of a patient suffering from psoriasis.

24. A method of treating bacterial infection comprising administering the composition of claim 1 to the site in need of said treatment.

25. A method of treating bacterial infection comprising the step of applying a pharmaceutical composition according to claim 5 to, or in the vicinity of, the infected region of a patient.

26. A method of treating bacterial infection comprising the step of applying a pharmaceutical composition according to claim 9 to or in the vicinity of the infected region of a patient.

27. A composition according to any one of claims 1 to 5 wherein the carrier is an ointment.

28. A method of topically treating local or systemic ailments substantially as hereinbefore described with reference to any one of the examples.

29. A pharmaceutical composition for topical administration to a patient in need thereof said composition substantially as hereinbefore defined with reference to any one of the examples.

30. A method of topically treating local or systemic ointments substantially as herinbefore described with reference to any one of the examples.



31. A pharmaceutical composition for topical administration to a patient in need thereof said composition substantially as herinbefore defined with reference to any one of the examples.

DATED this 20th day of AUGUST, 1991

SMITHKLINE BEECHAM CORPORATION

Attorney: IAN T. ERNST

Fellow Institute of Patent Attorneys of Australia
of SHELSTON WATERS



INTERNATIONAL SEARCH REPORT

International Application No. PCT/AU 89/00118

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

Int. Cl. ⁴ A61K 31/28, 31/70

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System

Classification Symbols

IPC

A61K 31/28, 31/70

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched *

AU : IPC as above

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
X	US,A, 4096250 (SMITHKLINE CORPORATION) 20 June 1978 (20.06.78) see claims 1 and 6.	(1-5,8-12, 19-20)
X	US,A, 3635945 (SMITH KLINE & FRENCH LABORATORIES) 18 January 1972 (18.01.72) see column 2, lines 22-26	(1-5,8-12, 19-20)
X	THE MERCK INDEX, Tenth Ed., Windholz et al, issued October 1983 by Merch & Co., Inc. (Rahway, N.J.) see page (126) compd. 882.	(1-5,8-12, 19-20)
Y	Chemical Abstracts, Volume 100, No.24, issued 1984, June 11 (Columbus, Ohio, U.S.A.) Fernandez Fernandez 'Auranofin preparation for arthritis treatment' see page 365, column 2, the abstract no. 197783v.	(1-5,8-12, 19-20)
A,Y	US,A, 4122254 (SMITHKLINE CORPORATION) 24 October 1978 (24.10.78)	(1-28)
A,Y	US,A, 4125710 (SMITHKLINE CORPORATION) 14 November 1978 (14.11.78)	(1-28)
A,Y	US,A, 4131732 (SMITHKLINE CORPORATION) 26 December 1978 (26.12.78)	(1-28)
A	US,A, 4657763 (MICHAEL EBERT) 14 April 1987 (14.04.87) see column 2, lines 27-37.	(1-28)

* Special categories of cited documents: **

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

27 June 1989 (27.06.89)

Date of Mailing of this International Search Report

3 July 1989

International Searching Authority

Australian Patent Office

Signature of Authorized Officer



R. DALBON

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.